InvaGen Pharmaceuticals, Inc. - Oct 11, 2022 Form 4 Insider Report for AVENUE THERAPEUTICS, INC. (ATXI)

Role
10%+ Owner
Signature
INVAGEN PHARMACEUTICALS INC. /s/ Deepak Agarwal By: Deepak Agarwal Title: Director
Stock symbol
ATXI
Transactions as of
Oct 11, 2022
Transactions value $
-$2,999,882
Form type
4
Date filed
10/13/2022, 08:52 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATXI Common Stock, par value $0.0001 per share Sale -$3M -389K -100% $7.71* 0 Oct 11, 2022 Direct F1, F2, F3
holding ATXI Common Stock, par value $0.0001 per share 0 Oct 11, 2022 See Footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

InvaGen Pharmaceuticals, Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This Form 4 is being jointly filed on behalf of (i) InvaGen Pharmaceuticals Inc., a New York corporation ("InvaGen"), (ii) Cipla (EU) Limited, a company incorporated in the United Kingdom ("Cipla EU"), and (iii) Cipla Limited, a company incorporated in India ("Cipla Limited") (each of InvaGen, Cipla EU and Cipla Limited, a "Reporting Person", and collectively, the "Reporting Persons"). InvaGen is a wholly-owned direct subsidiary of Cipla EU. Cipla EU is a wholly-owned direct subsidiary of Cipla Limited. Because of the relationship of InvaGen to Cipla EU and Cipla Limited, each such Reporting Person may be deemed to beneficially own the securities covered by this Form 4.
F2 On September 22, 2022, the common stock of Avenue Therapeutics, Inc. (the "Issuer") reverse split 1-for-15, resulting in the 5,833,333 shares of common stock of the Issuer previously reported by the Reporting Persons becoming 388,888 shares of common stock of the Issuer.
F3 On October 11, 2022, pursuant to the terms of the previously announced Stock Repurchase Agreement, dated July 25, 2022, among InvaGen, Fortress Biotech, Inc. and the Issuer, the Issuer repurchased 388,888 shares of common stock of the Issuer from InvaGen for an aggregate purchase price of $3,000,000 (the "Share Repurchase").
F4 As a result of the Share Repurchase and concurrent termination of the Voting and Support Agreement dated November 12, 2018, by and among InvaGen, Madison Pharmaceuticals Inc. and the Issuer, the Reporting Persons no longer have beneficial ownership of the securities previously reported as indirectly owned in the Reporting Persons' Form 3.